esc
Search documents
go
Browse entities
go
Corpus stats
go
About the data
go
AI settings
go
EFTA
Search
Search
Entities
About
Stats
Settings
⌘K
search
Search
Search syntax help
Dataset
Set 1
Set 2
Set 3
Set 4
Set 5
Set 6
Set 7
Set 8
Set 9
Set 10
Set 11
Set 12
Sort
Relevance
Most pages
Most words
Dataset
Newest
Oldest
Status
All
Extracted
Failed
DOJ Status
All
Removed
Available
Modified
Date Range
Undated only
–
Email Headers
Page Count
–
Saved Searches
+
14 results for “
"Teva Pharma"
”
Export
Keyboard Shortcuts
/
Focus search
Esc
Blur input
O
Open PDF
←
→
Paginate
EFTA00821586
Dataset 9
2016-08-08
6p
2,186w
Subject:
RE: Preferreds, thoughts on fixed income, mandatory converts
From:
"Ens, Amanda" < 1:,
To:
"
[email protected]
" <
[email protected]
>
…solid pipeline and flexibility to deploy capital to drive shareholder return. Next catalyst will be 2Q eamings/2H16 Outlook on 8/8. AGN Is on our firm's US-1list of best Investment Ideas.
Teva Pharma
(TEVA) - BAML reiterating BUY on TEVA after the FTCs approval of AGN generics deal. We continue to like TEVA's positioning In generic pharma where scale and product diversity are increasingly important. TWA remains one of our top picks In Spec Pharma. Frontier Comm…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00821586.pdf
EFTA02454071
Dataset 11
2016-08-08
12p
2,677w
Subject:
Re: Preferreds, thoughts on fixed income, mandatory converts
From:
jeffrey E. <
[email protected]
>
To:
Ens, Amanda; Richard Kahn
…solid pipeline and flexibility to deplo= capital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1list of best investment ideas.
Teva Pharma
(TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where scale and pro=uct diversity are increasingly important. TEVA remains one of our top pick= in Spec Pharma. Frontier Comm…
https://www.justice.gov/epstein/files/DataSet%2011/EFTA02454071.pdf
EFTA02454468
Dataset 11
2016-08-08
9p
1,838w
Subject:
RE: Preferreds, thoughts on fixed income, mandatory converts
From:
Ens, Amanda O>
To:
[email protected]
…N=xt catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm:=17;s US-1list of best investment ideas.
Teva Pharma
(TEVA) - BAML reiterating BUY on TEVA after the FTC's approval=of AGN generics deal. We continue to like TEVA's positioning in generic=pharma where scale and product diversity are increasingly important. TEVA =emains one of our top picks in Spec Pharma.<=span> Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post…
https://www.justice.gov/epstein/files/DataSet%2011/EFTA02454468.pdf
EFTA00822153
Dataset 9
2016-08-04
4p
1,564w
Subject:
Prefermds, thoughts on fixed income, mandatory converts
From:
"Ens, Amanda" •fl•
To:
"jeevacationtantail.com" <
[email protected]
>
…solid pipeline and flexibility to deploy capital to drive shareholder return. Next catalyst will be 2Q earnings/V.116 Outlook on 8/8. AGN Is on our firm's US-1list of best investment Ideas.
Teva Pharma
(TWA) - BAML reiterating BUY on TEVA after the FTCs approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where scale and product diversity are increasingly important. TWA remains one of our top picks in Spec Pharma. Frontier…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00822153.pdf
EFTA00821594
Dataset 9
2016-08-08
8p
2,362w
Subject:
Re: Preferreds, thoughts on fixed income, mandatory converts
From:
leffrey E. <
[email protected]
>
To:
"Ens, Amanda" •;: >
…solid pipeline and flexibility to deploy capital to drive shareholder return. Next catalyst will be 2Q earnings/2/116 Outlook on 8/8. AGN is on our firm's US-1list of best investment ideas.
Teva Pharma
(TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning In generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00821594.pdf
EFTA01737698
Dataset 10
2016-08-09
14p
2,836w
Subject:
RE: Preferreds, thoughts on fixed income, mandatory converts
From:
"Ens, Amanda"
To:
"Jeffrey E." <
[email protected]
>, Richard Kahn
…Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas.
Teva Pharma
(TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier Comm (FIR) - BAML reaffirming BUY after Frontier reported its first…
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01737698.pdf
EFTA01783152
Dataset 10
2016-08-08
12p
2,582w
Subject:
RE: Preferreds, thoughts on fixed income, mandatory converts
From:
Ens, Amanda
To:
Jeffrey E.
…solid pipeline and flexibility to deploy capital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1list of best investment ideas.
Teva Pharma
(TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier…
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01783152.pdf
EFTA01783231
Dataset 10
2016-08-08
13p
2,785w
Subject:
RE: Preferreds, thoughts on fixed income, mandatory converts
From:
Ens, Amanda
To:
jeffrey E.; Richard Kahn
…solid pipeline and flexibility to deploy capital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1list of best investment ideas.
Teva Pharma
(TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier…
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01783231.pdf
EFTA01785499
Dataset 10
2016-08-15
19p
3,544w
Subject:
RE: Preferreds, thoughts on fixed income, mandatory converts
From:
Ens, Amanda <
To:
jeffrey E.; Richard Kahn
…solid pipeline and flexibility to deploy capital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas.
Teva Pharma
(TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma…
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01785499.pdf
EFTA02454261
Dataset 11
2016-08-15
17p
3,300w
Subject:
RE: Preferreds, thoughts on fixed income, mandatory converts
From:
Ens, Amanda <
To:
jeffrey E.; Richard Kahn
…solid pipeline and flexibility to deploy capital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas.
Teva Pharma
(TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma…
https://www.justice.gov/epstein/files/DataSet%2011/EFTA02454261.pdf
EFTA02454560
Dataset 11
2016-08-15
17p
3,377w
Subject:
Re: Preferreds, thoughts on fixed income, mandatory converts
From:
jeffrey E. <
[email protected]
>
To:
Ens, Amanda; Richard Kahn
…solid pipeline and flexibility to deplo= capital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1list of best investment ideas.
Teva Pharma
(TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where scale and pro=uct diversity are increasingly important. TEVA remains one of our top pick= in Spec Pharma. Frontier Comm…
https://www.justice.gov/epstein/files/DataSet%2011/EFTA02454560.pdf
EFTA02455318
Dataset 11
2016-08-09
15p
2,997w
Subject:
Re: Preferreds, thoughts on fixed income, mandatory converts
From:
jeffrey E. <
[email protected]
>
To:
Ens, Amanda
…solid pipeline and flexibility to deplo= capital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1list of best investment ideas.
Teva Pharma
(TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where scale and pro=uct diversity are increasingly important. TEVA remains one of our top pick= in Spec Pharma. Frontier Comm…
https://www.justice.gov/epstein/files/DataSet%2011/EFTA02455318.pdf
EFTA02454699
Dataset 11
2016-08-15
18p
3,484w
Subject:
RE: Preferreds, thoughts on fixed income, mandatory converts
From:
Ens, Amanda <
To:
jeffrey E.; Richard Kahn
…solid pipeline and flexibility to deploy capital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1list of best investment ideas.
Teva Pharma
(TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier…
https://www.justice.gov/epstein/files/DataSet%2011/EFTA02454699.pdf
EFTA00422126
Dataset 9
2012-01-02
5p
1,376w
Subject:
Early Tour 1.2.12
From:
Henry Higdon <1
To:
Undisclosed recipients:;
…good" • Daimler is on track to boost O4 operating profit y/y and meet annual sales forecast says CFO in interview • ProSiebenSat.1 (PSM GY) says its market share in 2011 rose slightly from 28.5% to 28.9% •
Teva Pharma
names Jeremy Levin of BMY to replace ShIomo Yanai as CEO (trading +3.0% in Israel) • Archer Ltd trading lower in Oslo as CEO Jorgen Rasmussen leaves to pursue other interests (trading -3.7%) • Vestas Wind Systems (VWS DC…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00422126.pdf
Corpus: 1990-03-17 – 2025-12-01
←
August 2016
→
Mo
Tu
We
Th
Fr
Sa
Su
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Undated
(150,429)
None
Light
Medium
Heavy
Results by Dataset
14 total
Set 9
4
Set 10
4
Set 11
6